BioWorld

Feb. 19, 2003

La Jolla's Stock Tumbles After Failure Of Phase III Lupus Drug

An anticipated Phase III trial of Riquent in lupus, meant to confirm data trends seen in a Phase II/III trial, brought about a similar result - good data trends but a missed primary endpoint, sending La Jolla Pharmaceutical Co.'s stock down 72.5 percent. (BioWorld Today) Read More

SangStat, Abgenix Drop GVHD Drug On Poor Phase II/III Data

Bacillus thuringiensis Scores As Weapon Of Mass Destruction For Bollworm Insects Menacing Crops

Cost-Cutting Measures Taken At Gene Therapy Firm Introgen

$10M Private Placement Gives Onyx Added Phase III Funding

Dolly The Cloned Sheep Opened Research Doors In Biotechnology

Other News To Note

Appointments And Advancements

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for July 9, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...